Literature DB >> 12063478

Ofuji's disease: a report on 20 patients with clinical and histopathologic analysis.

Naoko Ishiguro1, Etsuko Shishido, Reiko Okamoto, Yasuko Igarashi, Mina Yamada, Makoto Kawashima.   

Abstract

BACKGROUND: Ofuji's disease, also referred to as classic eosinophilic pustular folliculitis, is a rare dermatosis of unknown origin for which there is no uniformly effective treatment. OBJECTIVES AND METHODS: Twenty patients with Ofuji's disease (classic eosinophilic pustular folliculitis) evaluated in our department from January 1978 to June 1999 were studied clinically and histopathologically. Laboratory data, treatments, and clinical courses were evaluated in 12 of these individuals.
RESULTS: Nissl modified staining revealed moderate increases of mast cells around hair follicles and sebaceous glands in all 20 patients; the majority of the infiltrating mast cells were tryptase-positive and chymase-negative. Eight of 11 patients treated with oral indomethacin responded completely.
CONCLUSIONS: Indomethacin is an effective therapy for Ofuji's disease. Tryptase-positive and chymase-negative mast cells might play some role in the pathogenesis of Ofuji's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063478     DOI: 10.1067/mjd.2002.120533

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Indomethacin inhibits eosinophil migration to prostaglandin D2 : therapeutic potential of CRTH2 desensitization for eosinophilic pustular folliculitis.

Authors:  Naoko Kataoka; Takahiro Satoh; Aiko Hirai; Kazumi Saeki; Hiroo Yokozeki
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

2.  Ofuji disease: a rare dermatosis and its challenging therapeutic approach.

Authors:  Fernanda Freitas de Brito; Antonio Carlos Ceribelli Martelli; Maria Lopes Lamenha Lins Cavalcante; Ana Cecília Versiani Duarte Pinto; Gabriela Itimura; Cleverson Teixeira Soares
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.